NRX Pharmaceuticals, Inc. financial data

Symbol
NRXP, NRXPW on Nasdaq
Location
Wilmington, DE
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 20% %
Debt-to-equity -128% % 3.2%
Return On Equity 139% % -14%
Return On Assets -490% % 1.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28,097,627 shares 132%
Common Stock, Shares, Outstanding 27,682,530 shares 143%
Entity Public Float $21,500,000 USD -28%
Common Stock, Value, Issued $28,000 USD 155%
Weighted Average Number of Shares Outstanding, Basic 22,231,178 shares 103%
Weighted Average Number of Shares Outstanding, Diluted 8,852,286 shares 33%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $242,000 USD
Cost of Revenue $97,000 USD
Research and Development Expense $1,429,000 USD 134%
General and Administrative Expense $2,743,000 USD -35%
Costs and Expenses $4,266,000 USD 41%
Operating Income (Loss) $4,024,000 USD -33%
Nonoperating Income (Expense) $1,866,000 USD -233%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $38,061,000 USD -47%
Earnings Per Share, Basic -0.27 USD/shares -80%
Earnings Per Share, Diluted -0.74 USD/shares 55%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $7,184,000 USD 336%
Accounts Receivable, after Allowance for Credit Loss, Current $239,000 USD
Other Assets, Current $128,000 USD
Assets, Current $11,947,000 USD 191%
Property, Plant and Equipment, Net $69,000 USD
Operating Lease, Right-of-Use Asset $350,000 USD
Intangible Assets, Net (Excluding Goodwill) $1,777,000 USD
Goodwill $610,000 USD
Other Assets, Noncurrent $243,000 USD -32%
Assets $14,996,000 USD 236%
Accounts Payable, Current $4,257,000 USD -13%
Employee-related Liabilities, Current $420,000 USD 30%
Accrued Liabilities, Current $5,296,000 USD 4.8%
Liabilities, Current $40,593,000 USD 100%
Liabilities $40,751,000 USD 75%
Accumulated Other Comprehensive Income (Loss), Net of Tax $0 USD
Retained Earnings (Accumulated Deficit) $307,256,000 USD -14%
Stockholders' Equity Attributable to Parent $25,755,000 USD -37%
Liabilities and Equity $14,996,000 USD 236%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,480,000 USD 5.2%
Net Cash Provided by (Used in) Financing Activities $7,585,000 USD 1820%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 27,682,530 shares 143%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,105,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,319,000 USD -92%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Deferred Tax Assets, Valuation Allowance $49,665,000 USD 11%
Operating Lease, Liability $347,000 USD
Depreciation $2,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $5,890,000 USD -262%
Lessee, Operating Lease, Liability, to be Paid $375,000 USD
Property, Plant and Equipment, Gross $93,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $121,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $202,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $28,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $39,753,000 USD 11%
Preferred Stock, Shares Authorized 50,000,000 shares 0%
Additional Paid in Capital $281,473,000 USD 12%
Share-based Payment Arrangement, Expense $197,000 USD -30%
Interest Expense $230,000 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%